Third Rock Ventures — Full Portfolio

BiotechCambridge, US

Robert Gould(Executive Officer, Director)in

BoardAlan Ezekowitz(Director)inJames Geraghty(Director)James Collins(Director)

Board seatMark Levin· per SEC Form D · $55M raise · filed Jul 2017

Co-investorsForesite Capital

BiotechArlington, US

Justin Hanes(Director)Kevin Pojasek(Executive Officer)Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)

Board seatRobert Tepper· per SEC Form D · $7M raise · filed Aug 2015

Co-investorsLongitude CapitalSR One Capital ManagementYsios CapitalAtlas VentureLux Capital

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.

BiotechSouth San Francisco, US

Bernard Coulie(Executive Officer, Director)inJohannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)in

BoardKevin Raidy(Director)

Board seatCharles HomcyNeil Exter· per SEC Form D · $62.1M raise · filed Jul 2018

Co-investorsMenlo VenturesAgent Capital

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)in

BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)

Board seatNeil ExterBarbara Weber· per SEC Form D · $100.3M raise · filed Nov 2019

Co-investorsBain Capital Life SciencesForesite CapitalNextech Invest

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)inAdam Crystal(Executive Officer)inDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)

BoardBarbara Weber(Executive Officer, Director)in

Board seatAlexis BorisyReid Huber· per SEC Form D

Co-investorsForesite CapitalNextech InvestNSG Ventures

NASDAQ-listed (VYGR) biotech in Lexington, MA developing AAV gene therapies and antibodies for neurological diseases.

BiotechLexington, US

Robin Swartz(Executive Officer)inAlfred Sandrock(Executive Officer, Director)Peter Pfreundschuh(Executive Officer)inSteven Hyman(Director)James A. Geraghty(Director)Grace Colon(Director)

Board seatMark Levin· per SEC Form D · filed Apr 2015

Co-investorsARCH Venture Partners

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

BiotechHealthtechMedical Devices

Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Craig B. Thompson, M.D.(Founder)Brian Goff(Chief Executive Officer)in

Co-investorsARCH Venture PartnersFlagship VenturesSamsara BioCapital

Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.

AI & Machine LearningBiotechMedical DevicesSan Francisco, US

Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in

Co-investorsRA CapitalSozo VenturesYosemite

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.

BiotechDeep TechHealthtechBoston, US

Andrea Ballabio(Founder)Beth Levine(Founder)Herbert Virgin(Founder)James Hurley(Founder)in

Co-investorsAstellas Venture Management LLCEisai Innovation, Inc.Ono Venture Investment, Inc.

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.

AI & Machine LearningBiotechDeep TechHealthtech

Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in

Co-investorsNexTech VenturesPfizer VenturesNextech InvestPfizer Venture InvestmentsShangBay Capital LLCAgent Capital

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)Michael Naill(Senior Vice President, Process and Product Development)in

Co-investorsBain Capital Life SciencesBiotechnology Value FundGV (Google Ventures)

Strateos develops remote access laboratory software and automation platforms that enable scientists to design, execute, and analyze experiments through cloud-based robotics and control systems.

AI & Machine LearningBiotechDeep TechRoboticsSaaSMenlo Park, US

Chris Krueger(Executive Officer)inMark Fischer-Colbrie(Executive Officer, Director)inDavid Lynch, PhD(Chief Executive Officer)Marc Siladi(Chief Operating Officer)in

BoardJoshua Wolfe(Director)Armen Vidian(Director)

Co-investorsDCVC (Data Collective)Lux CapitalBlueStone Venture PartnersHarmonix FundSilicon BadiaAlly Bridge Group+3 more

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsBain Capital Life SciencesGV (Google Ventures)

Vibe Bio funds and supports overlooked drug development programs by combining AI and capital to identify promising treatments and reduce funding gaps.

AI & Machine LearningBiotechEnterprise Software

Alok Tayi(CEO & Founder)in

Co-investors6th Man VenturesAlleyCorpUndeterred CapitalAlley Robotics Ventures

BiotechSan Mateo, US

Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in

BoardArthur Pappas(Director)Liam Ratcliffe(Director)

Board seatKevin Starr· per SEC Form D

Co-investorsPappas CapitalDomain AssociatesFidelity InvestmentsJennison Associates

BiotechNewton, US

Alexey Margolin(Executive Officer, Director)Louis Brenner(Executive Officer)

BoardAxel Bolte(Director)James Topper(Director)Stephen Kraus(Director)

Board seatRobert Tepper· per SEC Form D · $53M raise · filed Dec 2015

Co-investorsPontifax Venture CapitalFrazier Life Sciences

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)

BoardKEITH CRANDELL(Director)DAVID R. WALT(Director)in

Board seatMark Angelino· per SEC Form D · $215M raise · filed Nov 2021

Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupJanus Henderson Investors+3 more

BiotechSouth San Francisco, US

Ivana Djuretic(Executive Officer, Director, Promoter)inYik Andy Yeung(Executive Officer, Director, Promoter)

Board seatJeffrey TongReid Huber· per SEC Form D · $55M raise · filed Apr 2024

BiotechAnn Arbor, US

Julia C. Owens(Executive Officer, Director)

BoardCarol Gallagher(Director)James Topper(Director)William Harrington(Director)Randall Whitcomb(Director)

Board seatMary Lynne Hedley· per SEC Form D · $59.1M raise · filed Dec 2017

Co-investors5AM VenturesFrazier Life SciencesOsage University Partners

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)inNicholas Downing(Director)

Board seatJeb Keiper· per SEC Form D · $10M raise · filed Nov 2019

Co-investorsBain Capital Life SciencesBain CapitalBain Capital Tech OpportunitiesNEA SecondaryPolaris Partners

BiotechCambridge, US

Alexandra Glucksmann(Executive Officer, Director)Dominik Naczynski(Director)Chris Bowden(Director)Jake Simson(Director)Rosana Kapeller(Director)

Board seatAbbie CelnikerNeil Exter· per SEC Form D · $82.6M raise · filed Oct 2021

Co-investorsCasdin Capital

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)

Board seatRobert Tepper· per SEC Form D · $55.8M raise · filed Dec 2015

Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesVenrockThe Column Group

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

BiotechTewksbury, US

George J. Fazio(Executive Officer, Director)inDan B. Curtis(Executive Officer)

BoardPaul LaViolette(Director)inGerald Brunk(Director)inIrit Yaniv(Director)

Board seatKevin GillisMark Levin· per SEC Form D

Co-investorsAccelmed PartnersGeneral CatalystLumira VenturesSV Health Investors

Originator of Otarmeni (lunsotogene parvec-cwha), an FDA-approved gene therapy for genetic hearing loss; acquired by Regeneron in 2023.

Cambridge, US

Board seatNeil ExterCraig MuirKevin Starr· per SEC Form D

Co-investorsage1Samsara BioCapital

Jewel is a wearable patch cardioverter defibrillator designed to provide continuous protection from sudden cardiac arrest, using machine learning to minimize false alarms while requiring no daily maintenance for up to a week.

AI & Machine LearningHealthtechMedical DevicesSan Francisco, US

Uday N. Kumar(Executive Officer, Director)in

BoardRussell Hirsch(Director)Krishna Yeshwant(Director)inWilliam H. Kucheman(Director)

Board seatNeil Exter· per SEC Form D

Co-investorsDeerfield Management CompanyGV (Google Ventures)

BiotechCambridge, US

David A. Berry(Executive Officer, Director)Stephen Hurly(Executive Officer, Director)John McCabe(Executive Officer)Arthur P. DeCillis(Executive Officer)Gregory D. Perry(Executive Officer)Eric S. Furfine(Executive Officer)

Board seatAbbie Celniker· per SEC Form D · $996K raise · filed Apr 2018

BiotechCambridge, US

Ed Freedman(Executive Officer, Director)

BoardCary Pfeffer(Executive Officer, Director)in

PartnerCary Pfeffer· quoted

Board seatCharles HomcyRobert Tepper· per SEC Form D

South San Francisco, US

John Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in

BoardCharles Homcy, M.D.(Director)

Board seatKevin Starr· per SEC Form D

Co-investorsRA Capital

HealthtechCambridge, US

PETER THOMSON(Executive Officer)

BoardLOUIS BRENNER(Director)

Board seatAbbie CelnikerNeil Exter· per SEC Form D · filed Jul 2020

BiotechNew York, US

Joern Aldag(Executive Officer, Director)Reinhard Kandera(Executive Officer, Director)Paul-Henri Lambert(Director)Michael Kelly(Director)Julie O'Neill(Director)Sander van Deventer(Director)

Board seatChristoph Lengauer· per SEC Form D · filed Feb 2019

Co-investorsSofinnova Partners

BiotechInglewood, US

Anna M. Wu(Executive Officer, Director)Jeffrey D. Quan(Executive Officer)Benjamin Chen(Executive Officer)Jennifer Keppler(President and Chief Operating Officer)Christian Behrenbruch(Chief Executive Officer)

BoardIsaac Bright(Director)

Board seatAbbie Celniker· per SEC Form D · $9.5M raise · filed Apr 2016

BiotechCambridge, US

Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRichard Murray(Executive Officer, Director)

Board seatRobert KamenCary PfefferRobert Tepper· per SEC Form D

Co-investorsNextech Invest

Kamal Therapeutics is developing an intravenous recombinant human decorin as a treatment for dystrophic epidermolysis bullosa.

BiotechHealthtechHingham, US

Mark de Souza(Executive Officer, Director)Alexander Silver(Director)Hal Landy(Director)Joff Masukawa(Director)Deborah Ramsdell(Executive Officer, Director)

Board seatPhilip Reilly· per SEC Form D · $17.3M raise · filed Nov 2025

Ann Arbor-founded biopharmaceutical company developing small molecule immunomodulators for autoimmune diseases and cancer.

BiotechAnn Arbor, US

Gary Glick(Executive Officer, Director)Paul Sekhri(Executive Officer)Kathleen M. Metters(Executive Officer, Director)

BoardMichael Hayden(Director)Michael Steinmetz(Director)

Board seatRobert Kamen· per SEC Form D · filed Jun 2015

Co-investorsARCH Venture PartnersCanaan PartnersClarus

BiotechBoston, US

Gleb Kuznetsov(Executive Officer, Director)inPierce Ogden(Executive Officer, Director)in

BoardJory Bell(Director)Jeff Huber(Director)Steven Holtzman(Director)

Board seatSteven J. Kafka· per SEC Form D · $32.8M raise · filed Dec 2024

BiotechSouth San Francisco, US

Tassos Anastasios Gianakakos(Executive Officer, Director)

BoardMark Perry(Director)Katherine Bowdish(Director)

Board seatCharles HomcyKevin Starr· per SEC Form D · $46M raise · filed Apr 2015

Co-investorsForesite CapitalKhosla Ventures

BiotechCambridge, US

Richard Gaynor, M.D.(Executive Officer)inRobert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)inEric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Board seatRobert KamenRobert Tepper· per SEC Form D

Co-investorsNextech InvestSofinnova VenturesClal Biotechnology Industries

HealthtechBedford, US

Christopher von Jako(Executive Officer, Director)Judith M. Huber(Executive Officer)Charles Carignan(Executive Officer, Director)Eric Swanson(Director)

BoardRussell Hirsch(Director)

Board seatMark Levin· per SEC Form D

Co-investorsProspect Venture Partners

Faction is a venture capital firm that invests in cryptocurrency and blockchain projects at the seed and series A stages, focusing on entrepreneurs building fundamental utility across the technology stack.

BiotechCrypto & Web3New York, US

Oren Harnevo(Executive Officer, Director)Ronald Bianchini, Jr.(Executive Officer, Director)Roneil Rumburg(Cofounder)Ohad Finkelstein(Director)SAMUEL HARRISON(Managing Partner)inChristina Calvaneso(Executive Officer)

Board seatDavid KaufmanAbbie Celniker· per SEC Form D · filed Dec 2023

Co-investorsAccelAdaverseAlephAxeleo CapitalBluebird VenturesBright Pixel Capital+35 more

BiotechMt. Arlington, US

Paul Chaney(Executive Officer, Director)

BoardDavid Guyer(Director)Bruce Peacock(Director)Kevin Starr(Director)Lutz Giebel(Director)

Board seatAbbie Celniker· per SEC Form D

Co-investorsAstellas Venture Management LLCAgent CapitalSV Health Investors

BiotechChestnut Hill, US

Joseph Italiano(Director)inJonathan Thon(Director)Sven Erik Karlsson(Executive Officer)Peter Finn(Executive Officer)

Board seatPhilip Reilly· per SEC Form D · $26.4M raise · filed Aug 2019

Co-investorsBoston Harbor AngelsQiming HealthcareVivo Capital

BiotechCambridge, US

Gad Soffer(Executive Officer)Ryan Cohlhepp(Executive Officer)J. Duncan Higgons(Director)Jeffrey Bluestone(Director)Dan Matloff(Executive Officer)Sanjay Keswani(Executive Officer, Director)

Board seatAbbie CelnikerCary Pfeffer· per SEC Form D

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)inBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in

BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)in

Board seatNeil Exter· per SEC Form D · $40M raise · filed Dec 2015

Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsOrbiMed

BiotechHealthtechCambridge, US

Barry Greene(Executive Officer, Director)inKimi Iguchi(Executive Officer)inMichael Cloonan(Executive Officer)Anne Marie Cook(Executive Officer)Stephen J. Kanes(Executive Officer)Jeffrey M. Jonas(Executive Officer, Director)

Board seatKevin Starr· per SEC Form D · $650M raise · filed Jan 2021

Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in

Board seatJeffrey Tong· per SEC Form D · $150M raise · filed Jul 2023

Co-investorsCatalio Capital Management, LPRA CapitalSamsara BioCapitalVertex Ventures HC

Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.

BiotechBoston, US

Tasuku Kitada(Executive Officer, Director, Promoter)inJacob Becraft(Executive Officer, Director, Promoter)inSamta Kundu(Executive Officer)in

BoardAla Alenazi(Director)Pegah Ebrahimi(Director)

Board seatJeb Keiper· per SEC Form D · $120.1M raise · filed Mar 2026

Co-investorsJIC Venture Growth InvestmentsKinnevikPlayground GlobalAmgen VenturesANRIFPV+2 more

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)

BoardMichael Goller(Director)Peter Thompson(Director)

Board seatReid Huber· per SEC Form D

Co-investorsEcoR1 CapitalOrbiMedRA CapitalNovo HoldingsOsage University Partners

Lexington, US

Board seatJigar Raythatha· per SEC Form D · $120.1M raise · filed Dec 2025

Co-investorsAtlas VentureOpenSky Ventures

Developer of Aqvesme (mitapivat), an FDA-approved medicine for anemia in thalassemia.

Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.

BiotechHealthtechMedical DevicesMassachusetts, US

Daniel Orlando(Chief Executive Officer)inTasos Konidaris(Executive Officer)inMartin Paz(Executive Officer)inRobert Gallotto(Executive Officer)inDaniel Tasse(Executive Officer, Director)inWilliam Scheinler(Executive Officer)in

Co-investorsHealthQuest CapitalBessemer Venture PartnersFrazier Life Sciences

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)in

Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+4 more

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossovervenBio PartnersVida Ventures

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny Venture

Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine.

HealthtechCambridge, US

Tariq Kassum(Executive Officer, Director)inMichael Boretti(Executive Officer)Christoph Lengauer(Executive Officer, Director)

Co-investorsCatalio Capital Management, LPFast Track InitiativeAlexandriaCasdin CapitalGV (Google Ventures)

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCatalio Capital Management, LPCure VenturesVivo CapitalCatalio Capital ManagementNovo Holdings

Santa Barbara, US

Alan Heeger(Vice President and Manager)Gary Wilcox(Vice President and Manager)

Co-investorsCanaan Partners

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalInvus+2 more

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)Nicole Hadas(Chief Legal Officer)

Co-investorsB Capital GroupB4 CapitalF-Prime CapitalAlexandriaB CapitalQatar Investment Authority+1 more

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

Daphne Koller(CEO & Founder)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in

BoardRobert Nelsen(Director)Vijay Pande(Director)in

Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalGV (Google Ventures)HOF CapitalSoftBank Vision Fund+5 more

BiotechCambridge, US

David Scadden(Director)Bastiano Sanna(Executive Officer)Jason Gardner(Executive Officer, Director)

BoardMichael Bonney(Director)Bruce Booth(Director)Alexis Borisy(Director)

Co-investorsAccess IndustriesAlphabetAtlas VentureCasdin CapitalGV (Google Ventures)

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsNextech InvestAlexandriaCasdin CapitalCreacion VenturesGoldman SachsInvus+3 more

A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.

BiotechDeep TechMedical DevicesWilmington, US

Liangxing Wu(Executive Officer, Director)inWenqing Yao(Executive Officer, Director)inTing Feng(Director)

BoardReid Huber(Director)in

Co-investorsNextech InvestThe Innovation Space

Originator of Inlexzo (gemcitabine intravesical system), an FDA-approved treatment for certain bladder cancers; acquired by Johnson & Johnson in 2019.